On 14 November, Roche provided an update on their trial data for gantenerumab, a treatment for people with mild cognitive impairment (MCI) due to Alzheimer’s and mild Alzheimer’s dementia.
Disappointingly, the results of their Phase III GRADUATE studies did not meet their primary goal (endpoints) l for the clinical trial, aiming to slow clinical decline in people with early Alzheimer’s disease. Roche are expected to provide more information on the data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD), taking place 29 November – 2 December.
On the news, ADI CEO Paola Barbarino said:
Along with those living with dementia and carers, we were very disappointed to learn of this news. We would like to sincerely thank all of those who have contributed to this trial, especially those living with dementia and Alzheimer’s disease. Whilst this is undoubtedly a set-back, we are grateful for Roche’s commitment to continue to develop novel diagnostics and potential treatments for Alzheimer’s.
All study participants will be informed directly by the respective study site investigators about this update, and will receive information on next steps for any ongoing Gantenerumab studies.
ADI will continue to monitor developments and will provide relevant updates as and when they occur. If anyone involved in the trials has any concerns or questions, please contact us so that we can direct you to the appropriate team at Roche.
